Guggenheim Maintains Buy on Blueprint Medicines, Raises Price Target to $138
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Michael Schmitz maintains a Buy rating on Blueprint Medicines (NASDAQ:BPMC) and raises the price target from $130 to $138.
August 02, 2024 | 7:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guggenheim analyst Michael Schmitz maintains a Buy rating on Blueprint Medicines and raises the price target from $130 to $138.
The Buy rating and increased price target from a reputable analyst at Guggenheim is likely to positively impact investor sentiment and drive short-term price appreciation for Blueprint Medicines.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100